Wrapping Up 2024 and Launching Into 2025 with Cyto-Mine? Chroma!
Sphere Bio
We’re the droplet microfluidic technology company for single cell analysis. We work small so you can think big.
As we draw the year to a close, it’s the perfect time to reflect on an incredible 2024 at Sphere Fluidics.
We’ve been busy expanding the team?globally and welcomed our new CEO, Dale Levitzke, to lead us into the future.
On the innovation front, we've brought three?new assays to the market; Cyto-Cellect? PLUS, Cyto-Cellect? Mouse and, the new Cyto-Cellect??Fc?Fusion. Our hard work and dedication have also been recognized with outstanding accolades:?Gold in Investors in People?and the?Life Science Company of the Year Award from The Cambridge Independent.
Our top news this month:
NEW ASSAY:?Cyto-Cellect? Fc Fusion Assay Kit
The perfect solution for researchers and developers looking to achieve high-efficiency cell line development for Fc Fusion protein manufacturing.??
The Cyto-Mine? Chroma is launching at?SLAS 2025!
It's almost here - The Cyto-Mine? Chroma: our latest single-cell analysis and isolation platform.
We’re launching it at this year’s SLAS event in San Diego, USA.
Automate. Accelerate. Analyze millions of cells in a single day.
领英推荐
We Invest In People?– Gold Accreditation, with Denise Emsden, our Vice-President of People
"I recognized early on that we needed an external benchmark and two years ago, we started working towards Investors in People gold accreditation."
Lab & Life Scientist feature: Droplet microfluidics for single cell analysis ?
In the latest edition of Lab and Life Scientist?our CTO, Richard Hammond, discusses the future of droplet microfluidics in single-cell workflows. ?
Join us at these upcoming?events:
That's all from the team at Sphere Fluidics.
Stay tuned for more exciting updates and breakthroughs in our January edition!
The Cell-Espresso? Team